newsfilter
← Latest News
Business Wire·

DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that the first patient has been dosed in